Stimcell Energetics (STME) Cash from Operations Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 20.35% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -48.14% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 0.50% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 50.11% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -14.75% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 15.83% |
| 10 | Stimcell Energetics | - | - | - | 5.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 5.84% |
| Nov 30, 2025 | -3.14% |
| Aug 31, 2025 | -12.65% |
| May 31, 2025 | 14.82% |
| Feb 28, 2025 | 20.73% |
| Nov 30, 2024 | 47.92% |
| Aug 31, 2024 | 46.70% |
| May 31, 2024 | 39.80% |
| Feb 29, 2024 | 27.30% |
| Nov 30, 2023 | 37.42% |
| Aug 31, 2023 | 38.04% |
| May 31, 2023 | 51.91% |
| Feb 28, 2023 | 21.79% |
| Nov 30, 2022 | 37.42% |
| Aug 31, 2022 | 28.12% |
| May 31, 2022 | 2.50% |
| Feb 28, 2022 | 14.83% |
| Nov 30, 2021 | -90.74% |
| Aug 31, 2021 | -48.10% |
| May 31, 2021 | -68.78% |
| Feb 28, 2021 | -4.93% |
| Nov 30, 2020 | 13.78% |
| Aug 31, 2020 | -16.13% |
| May 31, 2020 | -5.92% |
| Feb 29, 2020 | -11.27% |
| Nov 30, 2019 | 0.52% |
| Aug 31, 2019 | -18.22% |
| May 31, 2019 | -6.78% |
| May 31, 2016 | -274.16% |